Feng-Yu Liu1, Ji-Ping Qi, Feng-Lin Xu, Ai-Ping Wu. 1. Department of Pathology, First Hospital of Harbin Medical University, Harbin 150001, Heilongjiang Province, China.
Abstract
AIM: To investigate the clinicopathological features of gastrointestinal stromal tumor (GIST) and to study the reference indexes for malignancy. METHODS: Fifty-two cases of primary GIST were distinguished from a group of gastrointestinal mesenchymal tumors using a panel of antibodies such as CD117 and CD34 by immunohistochemical SP method. Their biological behaviors were analyzed using the expression of p21WAF1 and Bax in 52 cases of GIST. RESULTS: Grossly, the tumor size was between 1.5 cm and 13 cm (mean: 5.5 cm). Focal areas of hemorrhage, necrosis, or small cyst formation could be seen. Microscopically, the tumor was composed of spindle cells (20 cases), epithelioid cells (20 cases) and mixed cells (12 cases). Immunohistochemically, CD117 and CD34 showed diffuse strong positive expressions, the positive rates were 98.1% and 92.3%. SMA, S-100, NSE, NF and MBP showed focal positive expressions, the positive rates were 48.1%, 28.8%, 25%, 21.2% and 42.3% respectively. Vimentins were all positive desmin and CgA were all negative. In normal adult stomach and intestine, the immunoreactive staining for CD117 and CD34 showed immunoreactive interstitial cells of Cajal in myenteric neuroplexus. Among the 52 cases of GIST, 27 were positive for p21WAF1 (51.9%), 29 for Bax (55.8%). The expression of p21WAF1 and Bax had no significent difference with the localization, size, histological subtype of GIST, but had a significent difference with the histological grade (P = 0.000, respectively). p21WAF1 expression had a positive correlation to Bax expression (r = 0.461, P = 0.001, kappa = 0.459). CONCLUSION: GIST has complicated arrangements and various cell types. Positivity of CD117 and CD34 is the most valuable factor in diagnosing GIST. Expression of p21WAF1 and Bax plays an important role in potential malignancy and malignancy rather than in benign GIST. p21WAF1 and Bax may be used as the markers in the assessment of GIST malignant potential.
AIM: To investigate the clinicopathological features of gastrointestinal stromal tumor (GIST) and to study the reference indexes for malignancy. METHODS: Fifty-two cases of primary GIST were distinguished from a group of gastrointestinal mesenchymal tumors using a panel of antibodies such as CD117 and CD34 by immunohistochemical SP method. Their biological behaviors were analyzed using the expression of p21WAF1 and Bax in 52 cases of GIST. RESULTS: Grossly, the tumor size was between 1.5 cm and 13 cm (mean: 5.5 cm). Focal areas of hemorrhage, necrosis, or small cyst formation could be seen. Microscopically, the tumor was composed of spindle cells (20 cases), epithelioid cells (20 cases) and mixed cells (12 cases). Immunohistochemically, CD117 and CD34 showed diffuse strong positive expressions, the positive rates were 98.1% and 92.3%. SMA, S-100, NSE, NF and MBP showed focal positive expressions, the positive rates were 48.1%, 28.8%, 25%, 21.2% and 42.3% respectively. Vimentins were all positive desmin and CgA were all negative. In normal adult stomach and intestine, the immunoreactive staining for CD117 and CD34 showed immunoreactive interstitial cells of Cajal in myenteric neuroplexus. Among the 52 cases of GIST, 27 were positive for p21WAF1 (51.9%), 29 for Bax (55.8%). The expression of p21WAF1 and Bax had no significent difference with the localization, size, histological subtype of GIST, but had a significent difference with the histological grade (P = 0.000, respectively). p21WAF1 expression had a positive correlation to Bax expression (r = 0.461, P = 0.001, kappa = 0.459). CONCLUSION: GIST has complicated arrangements and various cell types. Positivity of CD117 and CD34 is the most valuable factor in diagnosing GIST. Expression of p21WAF1 and Bax plays an important role in potential malignancy and malignancy rather than in benign GIST. p21WAF1 and Bax may be used as the markers in the assessment of GIST malignant potential.
Authors: Isabelle Ray-Coquard; Axel Le Cesne; Véronique Michallet; Ioannis Boukovinas; Dominique Ranchere; P Thiesse; Vincent Baty; Jean-Yves Blay Journal: Bull Cancer Date: 2003-01 Impact factor: 1.276
Authors: Beate Rau; Isrid Sturm; Hermann Lage; Stefan Berger; Ulrike Schneider; Steffen Hauptmann; Peter Wust; Hanno Riess; Peter M Schlag; Bernd Dörken; Peter T Daniel Journal: J Clin Oncol Date: 2003-07-28 Impact factor: 44.544
Authors: C J van der Woude; J H Kleibeuker; A T G M Tiebosch; M Homan; A Beuving; P L M Jansen; H Moshage Journal: J Clin Pathol Date: 2003-09 Impact factor: 3.411
Authors: Julian Dorn; Hanno Spatz; Michael Schmieder; Thomas Fe Barth; Annette Blatz; Doris Henne-Bruns; Uwe Knippschild; Klaus Kramer Journal: BMC Cancer Date: 2010-07-02 Impact factor: 4.430
Authors: Maxwel Capsy Boga Ribeiro; Luiz Roberto Lopes; João Coelho de Souza Neto; Luciana Rodrigues Meirelles; Rita Barbosa de Carvalho; Nelson Adami Andreollo Journal: Case Rep Med Date: 2012-04-17